TY - JOUR
T1 - Inactivation of the urdGT2 gene, which encodes a glycosyltransferase responsible for the C-glycosyltransfer of activated D-olivose, leads to formation of the novel urdamycins I, J, and K
AU - Künzel, Eva
AU - Faust, Bettina
AU - Oelkers, Carsten
AU - Weissbach, Ulrike
AU - Bearden, Daniel W.
AU - Weitnauer, Gabriele
AU - Westrich, Lucia
AU - Bechthold, Andreas
AU - Rohr, Jürgen
PY - 1999/12/8
Y1 - 1999/12/8
N2 - A targeted search for glycosyltransferase (GT) encoding genes in the gene cluster of the urdamycin A producer Streptomyces fradiae Tu2717 resulted in the discovery of urdGT2, a GT encoding gene located approximately 7 kb downstream of the minimal polyketide synthase (PKS) encoding genes. Subsequent inactivation of this gene created a mutant strain, which produces completely different metabolites than the wild-type strain, consisting of the three new urdamycins I, J, and K. Their structures provide new insight into the important C-glycosyl-transfer step of the urdamycin biosynthetic pathway. The structures indicate that the corresponding gene product UrdGT2 catalyzes the C-glycosyl transfer of activated D-olivose to an angucyclinone precursor, which already bears the angular 12b-OH group. The structures of the new urdamycins could not have arisen without the involvement of substrate flexible post-PKS modifying genes, i.e., glycosyltransferases and oxidoreductases. This work proves that targeted gene disruption experiments can lead to novel biologically active 'unnatural' natural products, which arise through a formerly nonactivated shunt pathway. This approach is especially fruitful in work toward antitumor drugs. Urdamycin J shows a good anticancer activity in in vitro tests.
AB - A targeted search for glycosyltransferase (GT) encoding genes in the gene cluster of the urdamycin A producer Streptomyces fradiae Tu2717 resulted in the discovery of urdGT2, a GT encoding gene located approximately 7 kb downstream of the minimal polyketide synthase (PKS) encoding genes. Subsequent inactivation of this gene created a mutant strain, which produces completely different metabolites than the wild-type strain, consisting of the three new urdamycins I, J, and K. Their structures provide new insight into the important C-glycosyl-transfer step of the urdamycin biosynthetic pathway. The structures indicate that the corresponding gene product UrdGT2 catalyzes the C-glycosyl transfer of activated D-olivose to an angucyclinone precursor, which already bears the angular 12b-OH group. The structures of the new urdamycins could not have arisen without the involvement of substrate flexible post-PKS modifying genes, i.e., glycosyltransferases and oxidoreductases. This work proves that targeted gene disruption experiments can lead to novel biologically active 'unnatural' natural products, which arise through a formerly nonactivated shunt pathway. This approach is especially fruitful in work toward antitumor drugs. Urdamycin J shows a good anticancer activity in in vitro tests.
UR - http://www.scopus.com/inward/record.url?scp=0033537033&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033537033&partnerID=8YFLogxK
U2 - 10.1021/ja9915347
DO - 10.1021/ja9915347
M3 - Article
AN - SCOPUS:0033537033
SN - 0002-7863
VL - 121
SP - 11058
EP - 11062
JO - Journal of the American Chemical Society
JF - Journal of the American Chemical Society
IS - 48
ER -